» Articles » PMID: 28776152

Glucose Metabolism Parameters and Post-Prandial GLP-1 and GLP-2 Release Largely Vary in Several Distinct Situations: a Controlled Comparison Among Individuals with Crohn's Disease and Individuals with Obesity Before and After Bariatric Surgery

Overview
Journal Obes Surg
Date 2017 Aug 5
PMID 28776152
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: This study aims to compare the post-prandial curves of glucose, insulin, GLP-1, and GLP-2 among individuals with Crohn's disease (CD), obese individuals before and after bariatric surgery, and healthy controls.

Methods: This an exploratory cross-sectional study that involved five groups of patients (two groups of individuals with CD-active and inactive), bariatric patients (pre- and post-surgery, who were their own controls), and a distinct separated control group of healthy volunteers. C-reactive protein (CRP) levels and the post-prandial curves of glucose, insulin, GLP-1, and GLP-2 curves were assessed and compared.

Results: The pre-RYGB group presented significantly higher levels of CRP than the post-RYGB (p = 0.001) and the control group (p = 0.001). The inactive CD group presented a higher post-prandial GLP-1 area under the curve (AUC) than the pre-RYGB group (p = 0.009). The post-RYGB group presented significantly higher AUCs of GLP-2 than the pre-RYGB group (p < 0.0001), both inactive and active CD groups (p < 0.0001 in both situations), and the control group (p = 0.002). The pre-RYGB group presented a significantly higher AUC of glucose than the post-RYGB (p = 0.02) and both active and inactive CD groups (p = 0.019 and p = 0.046, respectively). The pre-RYGB group presented a significantly higher AUC of insulin than the control (p = 0.005) and both CD groups (p < 0.0001).

Conclusions: Obesity is associated with an inflammatory state comparable to the one observed in CD; inflammation may also be enrolled in the blockade of GLP-2. CD individuals present a more incretin-driven pattern of glucose metabolism, as a way to prevent hypoglycemia and compensate the carbohydrate malabsorption and GLP-2 blockade.

Citing Articles

Plasma glucagon-like peptide-2 in cats with chronic enteropathies.

Jugan M, Plattner B, Ford A, Freilich L, Bieberly Z, Schermerhorn T J Feline Med Surg. 2025; 27(1):1098612X241305923.

PMID: 39840661 PMC: 11755514. DOI: 10.1177/1098612X241305923.


Noninvasive Colorectal Cancer Screening in Bariatric Surgery Patients As a Viable Option to Increase Uptake.

Wilder E, Fakhreddine A Gastro Hep Adv. 2024; 2(7):1014-1015.

PMID: 39130761 PMC: 11307808. DOI: 10.1016/j.gastha.2023.08.018.


Evaluation of the relationship between plasma glucagon-like peptide-2 and gastrointestinal dysbiosis in canine chronic enteropathies.

Voudren C, Mayhue E, Riehm M, Jugan M PLoS One. 2024; 19(6):e0305711.

PMID: 38935795 PMC: 11210855. DOI: 10.1371/journal.pone.0305711.


Post metabolic bariatric surgery weight regain: the importance of GLP-1 levels.

Calik Basaran N, Dotan I, Dicker D Int J Obes (Lond). 2024; .

PMID: 38225284 DOI: 10.1038/s41366-024-01461-2.


Progress and Clinical Applications of Crohn's Disease Exclusion Diet in Crohn's Disease.

Xu D, Peng Z, Li Y, Hou Q, Peng Y, Liu X Gut Liver. 2023; 18(3):404-413.

PMID: 37842728 PMC: 11096903. DOI: 10.5009/gnl230093.


References
1.
Caradonna L, Amati L, Magrone T, Pellegrino N, Jirillo E, Caccavo D . Enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel disease: biological and clinical significance. J Endotoxin Res. 2000; 6(3):205-14. View

2.
Olszanecka-Glinianowicz M, Zahorska-Markiewicz B, Janowska J, Zurakowski A . Serum concentrations of nitric oxide, tumor necrosis factor (TNF)-alpha and TNF soluble receptors in women with overweight and obesity. Metabolism. 2004; 53(10):1268-73. DOI: 10.1016/j.metabol.2004.07.001. View

3.
Tsukahara T, Watanabe K, Watanabe T, Yamagami H, Sogawa M, Tanigawa T . Tumor necrosis factor α decreases glucagon-like peptide-2 expression by up-regulating G-protein-coupled receptor 120 in Crohn disease. Am J Pathol. 2014; 185(1):185-96. DOI: 10.1016/j.ajpath.2014.09.010. View

4.
Sigalet D, Kravarusic D, Butzner D, Hartmann B, Holst J, Meddings J . A pilot study examining the relationship among Crohn disease activity, glucagon-like peptide-2 signalling and intestinal function in pediatric patients. Can J Gastroenterol. 2013; 27(10):587-92. PMC: 3805340. DOI: 10.1155/2013/460958. View

5.
. Gastrointestinal surgery for severe obesity: National Institutes of Health Consensus Development Conference Statement. Am J Clin Nutr. 1992; 55(2 Suppl):615S-619S. DOI: 10.1093/ajcn/55.2.615s. View